An Exploratory Phase 2a Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of MEDI0382 versus Placebo in Overweight/Obese Subjects with Type 2 Diabetes Mellitus Treated with Dapagliflozin and Metformin
Phase of Trial: Phase II
Latest Information Update: 11 Jan 2019
At a glance
- Drugs MEDI 0382 (Primary) ; Dapagliflozin; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors MedImmune
- 04 Jan 2019 Status changed from active, no longer recruiting to completed.
- 18 Oct 2018 Planned End Date changed from 18 Dec 2018 to 10 Dec 2018.
- 18 Oct 2018 Planned primary completion date changed from 18 Dec 2018 to 10 Dec 2018.